Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Lonza is set to invest £16m in its Slough, UK biopharmaceutical manufacturing facility so as to get a range of customer projects and strengthen its global network of biologics development and manufacturing.
Subscribe to our email newsletter
The company is constructing a new 60,000sqft building adjacent to existing buildings to create a Slough campus.
Lonza‘s Slough site is into developing and manufacturing antibodies and therapeutic proteins that are used in the clinical stages of drug development and ongoing commercial supply of marketed biopharmaceutical products.
Slough manufacturing site houses a small-scale pilot plant and a range of GMP production reactor capacities between 200 and 2000 liters.
Lonza Slough Facility head Gordon Bates said they are delighted with the investment and eager to push on and realize the benefits of the investment for both their employees and the customers."
"The project is scheduled for completion by the end of 2012 with no disruption to ongoing activities," Bates said.